Kiniksa Pharmaceuticals, Ltd. (KNSA)
Largest Insider Buys in Sector
KNSA Stock Price History Chart
KNSA Stock Performance
About Kiniksa Pharmaceuticals, Ltd.
Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell …
Insider Activity of Kiniksa Pharmaceuticals, Ltd.
Over the last 12 months, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $16.4M worth of Kiniksa Pharmaceuticals, Ltd. stock.
On average, over the past 5 years, insiders at Kiniksa Pharmaceuticals, Ltd. have bought $0 and sold $7.64M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 1,686,704 shares for transaction amount of $31.99M was made by Flynn James E (10 percent owner) on 2018‑05‑29.
List of Insider Buy and Sell Transactions, Kiniksa Pharmaceuticals, Ltd.
| 2024-12-16 | Sale | CHIEF OPERATING OFFICER | 23,017 0.0323% | $20.44 | $470,467 | +1.08% | ||
| 2024-12-09 | Sale | CHIEF FINANCIAL OFFICER | 18,860 0.0261% | $21.38 | $403,227 | -3.89% | ||
| 2024-12-06 | Sale | CHIEF FINANCIAL OFFICER | 8,969 0.0123% | $21.27 | $190,771 | -4.51% | ||
| 2024-12-05 | Sale | CHIEF FINANCIAL OFFICER | 1,123 0.0016% | $21.25 | $23,864 | -1.86% | ||
| 2024-12-03 | Sale | CHIEF FINANCIAL OFFICER | 8,969 0.0128% | $21.45 | $192,385 | -0.90% | ||
| 2024-11-29 | Sale | CHIEF ACCOUNTING OFFICER | 9 <0.0001% | $22.45 | $202 | -4.30% | ||
| 2024-11-18 | Sale | CHIEF OPERATING OFFICER | 17,000 0.023% | $21.04 | $357,680 | 0.00% | ||
| 2024-11-06 | Sale | CHAIRMAN & CEO | 89,561 0.1239% | $23.00 | $2.06M | -7.49% | ||
| 2024-10-15 | Sale | CHIEF OPERATING OFFICER | 17,000 0.0268% | $26.87 | $456,790 | -19.35% | ||
| 2024-09-23 | Sale | CHIEF OPERATING OFFICER | 17,500 0.0249% | $24.99 | $437,325 | -8.12% | ||
| 2024-09-03 | Sale | CHIEF MEDICAL OFFICER | 60,692 0.0855% | $26.12 | $1.58M | -10.98% | ||
| 2024-09-03 | Sale | CHIEF COMMERCIAL OFFICER | 68,506 0.0966% | $26.12 | $1.79M | -10.98% | ||
| 2024-08-27 | Sale | CHIEF OPERATING OFFICER | 17,500 0.0244% | $26.91 | $470,925 | -11.73% | ||
| 2024-07-23 | Sale | CHAIRMAN & CEO | 136,124 0.1877% | $25.65 | $3.49M | +1.00% | ||
| 2024-07-23 | Sale | CHIEF MEDICAL OFFICER | 22,000 0.0311% | $26.32 | $578,966 | -1.54% | ||
| 2024-07-23 | Sale | CHIEF FINANCIAL OFFICER | 24,248 0.0323% | $24.79 | $601,108 | +4.52% | ||
| 2024-03-07 | Sale | CHAIRMAN & CEO | 65,012 0.0919% | $21.02 | $1.37M | -0.80% | ||
| 2024-03-06 | Sale | CHAIRMAN & CEO | 5,582 0.008% | $21.00 | $117,222 | +0.62% | ||
| 2024-03-04 | Sale | CHAIRMAN & CEO | 12,742 0.0194% | $21.49 | $273,834 | +4.19% | ||
| 2024-03-01 | Sale | CHIEF OPERATING OFFICER | 1,189 0.0017% | $22.03 | $26,194 | -3.50% |
Insider Historical Profitability
| Patel Sanj K | CHAIRMAN & CEO | 79551 0.1102% | $20.37 | 1 | 11 | |
| BAKER BROS. ADVISORS LP | 2700597 3.7404% | $20.37 | 2 | 0 | +4.3% | |
| Cormorant Asset Management, LP | director | 900443 1.2471% | $20.37 | 1 | 0 | +4.3% |
| Flynn James E | 10 percent owner | 843352 1.1681% | $20.37 | 1 | 0 | +4.3% |
| Beetham Thomas W. | EVP & Chief Legal Officer | 297523 0.4121% | $20.37 | 1 | 6 |
Institutional Investor Ownership
| BlackRock | $82.75M | 5.91 | 4.19M | +31.86% | +$19.99M | <0.01 | |
| Fairmount Funds Management LLC | $63.23M | 4.52 | 3.2M | +11.15% | +$6.35M | 6.89 | |
| Hillhouse Capital Advisors Ltd | $61.87M | 4.42 | 3.14M | New | +$61.87M | 1.35 | |
| The Vanguard Group | $58.83M | 4.2 | 2.98M | +0.56% | +$327,419.35 | <0.01 | |
| Baker Bros Advisors LP | $55.43M | 3.96 | 2.81M | 0% | +$0 | 0.4 |